Overview

This trial is active, not recruiting.

Conditions hiv infection, alcohol use
Treatments zinc gluconate, placebo
Phase phase 2/phase 3
Sponsor Boston Medical Center
Collaborator National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Start date October 2013
End date March 2017
Trial size 250 participants
Trial identifier NCT01934803, U01AA021989

Summary

This study is a double-blinded randomized controlled trial (RCT) to assess the efficacy of zinc supplementation vs. placebo among 250 HIV-infected Russians from the Russia ARCH Cohort, who are ART-naive at enrollment and have a recent history of heavy drinking.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Active Comparator)
Study participants will receive zinc gluconate supplements (15 mg for men and 12 mg for women) and will be instructed to take one pill daily for 18 months.
zinc gluconate
Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
(Placebo Comparator)
Study participants will receive identically packaged placebo (sucrose) pills and will be instructed to take one pill daily for 18 months.
placebo

Primary Outcomes

Measure
Improved markers of mortality as measured by change in VACS index
time frame: Participants will be followed for up to 18 months

Secondary Outcomes

Measure
Slower HIV disease progression as measured by change in CD4 cell count
time frame: Participants will be followed for up to 18 months
Improved markers of AMI risk as measured by the Reynolds risk score
time frame: Participants will be followed for up to 18 months
Lower biomarker levels of microbial translocation and inflammation as measured by sCD-14, IL-6, D-dimer, 16sRDNA
time frame: Participants will be followed for up to 18 months

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - Age 18-70 years old - HIV-infected - ART naïve - Heavy alcohol consumption [i.e., NIAAA at-risk drinking levels] in the past 30 days - Provision of contact information for two contacts to assist with follow-up; - Stable address within St. Petersburg or districts within 100 kilometers of St. Petersburg; - Possession of a home or cellular telephone Exclusion Criteria: - Not fluent in Russian - Cognitive impairment resulting in inability to provide informed consent based on assessor assessment - Pregnancy - Breastfeeding

Additional Information

Official title Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort
Principal investigator Jeffrey Samet, MD, MA, MPH
Description The combination of heavy alcohol consumption and HIV infection is associated with increased mortality, HIV disease progression, acute myocardial infarction (AMI) and a proinflammatory state characterized by increased biomarker levels of inflammation. Heavy alcohol use and HIV infection are both causes of microbial translocation, the process by which bacterial products from the gastrointestinal (GI) tract leak across the GI membrane to the portal circulation. Microbial translocation causes immune activation leading to end organ damage. Alcohol can cause microbial translocation via zinc deficiency. Zinc deficiency is common among HIV-infected heavy drinkers and linked to high mortality rates. Zinc supplementation is affordable, available, does not interfere with ART, and has minimal adverse drug reactions. In animal models zinc reduces ethanol associated microbial translocation. In human studies zinc slows HIV disease progression and reduces levels of inflammatory biomarkers which are strongly linked to mortality. Given zinc's potential efficacy we propose to conduct Zinc for INflammation and Chronic disease in HIV (ZINC HIV), a double-blinded randomized controlled trial to assess the efficacy of zinc supplementation vs. placebo among 250 HIV+ Russians, who are ART-naive at enrollment and have a recent history of heavy drinking. We will recruit most of our participants from the Russia cohort within the Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Consortium study. Our specific aims will test the efficacy of zinc supplementation, compared to placebo to (1) improve markers of mortality as measured by the VACS index; (2) slow HIV disease progression as measured by CD4 cell count; (3) improve markers of AMI risk as measured by the Reynolds risk score; and (4) lower levels of microbial translocation and inflammation as measured by serum biomarkers. We hypothesize that as compared with placebo, patients receiving zinc supplementation will have significantly lower AMI and mortality risk as measured by the VACS index and Reynolds risk scores; higher CD4 cell counts; lower levels of biomarkers for microbial translocation and inflammation. Importantly, if our hypotheses are true, zinc supplementation could ultimately become a standard adjunctive therapy complementing alcohol interventions among HIV-infected persons even in resource limited environments. PUBLIC HEALTH RELEVANCE: The combination of heavy alcohol consumption and HIV infection results in serious health problems and an increased risk of death. Although it is not exactly clear how alcohol and HIV do this, inflammation appears to play an important role. Zinc supplementation has anti-inflammatory properties. This study is designed to see if giving zinc supplementation to HIV infected people who are heavy drinkers reduces the risk of serious health problems and death.
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by Boston Medical Center.